Small-Cap News: Smith & Wesson Holding Corp (SWHC)’s Announcement, Mellanox Technologies, Ltd. (MLNX), Catalyst Pharmaceutical Partners, Inc. (CPRX) & China Commercial Credit Inc (CCCR)’s Loan Guarantees

Stocks Buzz: Smith & Wesson Holding Corp (NASDAQ:SWHC), First Niagara Financial Group Inc. (NASDAQ:FNFG, TiVo Inc. (NASDAQ:TIVO), PMC-Sierra Inc (TechSonian)
VipStockReports.com screens the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. …Smith & Wesson Holding Corp (NASDAQ:SWHC) opened the session at $11.21, remained amid the day range of $10.99 – $11.30, and closed the session at $11.02. The stock showed a negative performance of -1.69% in previous trading session. The stock gained a volume of 1.90 million shares and the average volume of the stock remained 2.36 million shares. Will SWHC Get Buyers Even After The Recent Rally?

Should You Avoid Mellanox Technologies, Ltd. (MLNX)? (InsiderMonkey)
In today’s marketplace, there are a multitude of metrics investors can use to monitor stocks. A duo of the most useful are hedge fund and insider trading movement. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best investment managers can beat the market by a significant amount (see just how much). …Due to the fact Mellanox Technologies, Ltd. (NASDAQ:MLNX) has faced declining interest from upper-tier hedge fund managers, it’s safe to say that there exists a select few funds who sold off their entire stakes at the end of the second quarter.

Catalyst Pharmaceutical Partners Receives Breakthrough Therapy Designation From FDA for Firdapse(TM) for the Treatment of LEMS (Nasdaq)
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today announced that its investigational product Firdapse™ (amifampridine phosphate) has received “Breakthrough Therapy Designation” by the U.S. Food and Drug Administration (FDA) for the symptomatic treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse™ is Catalyst’s investigational therapy that is being evaluated for the treatment of the debilitating symptoms associated with LEMS, including muscle weakness.

China commercial credit IPO (ECNS)
A small Chinese financial company is creating a stir among some U.S. investors. China Commercial Credit Inc (NASDAQ:CCCR), whose subsidiary underwrites microloans to small companies in China’s Jiangsu province, emerged from its first week of trading on Nasdaq, up 40 percent to around nine dollars per share. Is this a sign of renewed U.S. interest in Chinese stocks, and what does it mean for China’s shadow banking system? For China Commercial Credit Inc (NASDAQ:CCCR), this was a volatile first week that ended on a high note. Its U.S. reception when it launched August 14th was lukewarm-with the IPO raising only $8.9 million dollars.